Drugs / RO7617991
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06372574 | Sep 2024 → Feb 2028 | cancer | Genentech, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7617991 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06372574 ↗ |
| Route | Intravenous | “RO7617991 will be administered by intravenous (IV) infusion.” NCT06372574 ↗ |